A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia

Dawn I Velligan, David Roberts, Jim Mintz, Natalie Maples, Xueying Li, Elisa Medellin, Matt Brown, Dawn I Velligan, David Roberts, Jim Mintz, Natalie Maples, Xueying Li, Elisa Medellin, Matt Brown

Abstract

Introduction: Among individuals with schizophrenia, those who have persistent and clinically significant negative symptoms (PNS) have the poorest functional outcomes and quality of life. The NIMH-MATRICS Consensus Statement indicated that these symptoms represent an unmet therapeutic need for large numbers of individuals with schizophrenia. No psychosocial treatment model addresses the entire constellation of PNS.

Method: 51 patients with PNS were randomized into one of two groups for a period of 9 months: 1) MOtiVation and Enhancement (MOVE) or 2) treatment as usual. MOVE is a home based, manual-driven, multi-modal treatment that employs a number of cognitive and behavioral principles to address the broad range of factors contributing to PNS and their functional consequences. The components of MOVE include: Environmental supports to prompt initiation and persistence, in-vivo skills training to ameliorate deficits and encourage interaction, cognitive behavioral techniques to address self-defeating attitudes, in-vivo training in emotional processing to address affective blunting and problems in identifying emotions, and specific techniques to address the deficits in anticipatory pleasure. Patients were assessed at baseline and each 3 months with multiple measures of negative symptoms.

Results: Repeated measures analyses of variance for mixed models indicated significant Group by Time effects for the Negative Symptom Assessment (NSA; p<.02) and the Clinical Assessment Interview for Negative Symptoms (CAINS; p<.04). Group differences were not significant until 9 months of treatment and were not significant for the Brief Negative Symptom Scale (BNSS).

Conclusion: Further investigation of a comprehensive treatment for PNS, such as MOVE, is warranted.

Keywords: Clinical Assessment Interview for Negative Symptoms; MOtiVation and Enhancement (MOVE) Training; Negative Symptom Assessment; Negative symptoms; Schizophrenia.

Conflict of interest statement

There are no conflicts of interest to report.

Published by Elsevier B.V.

Figures

Figure 1
Figure 1
Subject recruitment and retention
Figure 2
Figure 2

References

    1. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):225–30.
    1. Alphs L, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25(2):159–63.
    1. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res. 1993;27(3):253–258.
    1. Beck AT, Rector NA, Stolar N, Grant P. Schizophrenia: Cognitive Theory, Research, and Therapy. New York: The Guilford Press; 2009.
    1. Bellack AS, Mueser KT, Gingerich S, Agresta J. Social skills training for schizophrenia: A step-by-step guide. 2. New York: The Guilford Press; 2004.
    1. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239–46.
    1. Buchanan R. Persistent negative symptoms in schizophrenia: An overview. Schizophr Bull. 2007;33(4):1013–22.
    1. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5–19.
    1. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007b;164(10):1593–1602.
    1. Buchanan RW, Keefe RSE, Umbricht D, et al. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011;37(6):1209–1217.
    1. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander WM, Xianwei H, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. Journal of clinical psychopharmacology. 2012;32(1):36–45.
    1. Cohen J. Statistical power for the behavioral sciences. 2. Lawrence Erlbaum; Hillsdale, NJ: 1988.
    1. Forbes C, Blanchard JJ, Bennett M, et al. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS) Schizophr Res. 2010;124(1–3):36–42.
    1. Frith CD. The cognitive neuropsychology of schizophrenia. East Sussex, United Kingdom: Erlbaum Taylor & Francis; 1992.
    1. Gard DE, Kring AM, Germans Gard M, Horan WP, Green MF. Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–60.
    1. Gard DE, Sanchez AH, Starr J, Cooper S, Fishers M, Rowlands A, Vinogradov S. Using self-determination theory to understand motivation deficits in schizophrenia: the “why” of motivated behavior. Schizophr Res. 2014;156:217–222.
    1. Goldstein R, Volkow N. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry. 2002;159(10):1642–52.
    1. Granholm E, Ben-Zeev D, Link PC. Social disinterest attitudes and group cognitive-behavioral social skills training for functional disability in schizophrenia. Schizophr Bull. 2009;35(5):874–83.
    1. Ho B, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155:1196–1201.
    1. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Hein A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29:409–16.
    1. Kirkpatrick B, Buchanan R, Ross D, Carpenter W. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–71.
    1. Kirkpatrick B, Fenton WS, Carpenter WT, Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219.
    1. Kirkpatrick B, Hack G, Higginbottom E, Hoffacker D, Fernandez-Egea E. Palate and dentition in schizophrenia. Schizophr Res. 2007;91(1–3):187–91.
    1. Kirkpatrick B, Strauss GP, Nguyen L, et al. The Brief Negative Symptom Scale: Psychometric Properties. Schizophr Bull. 2011;37(2):300–305.
    1. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB Schizophrenia Patient Outcomes Research Team (PORT) The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2009;36(1):94–103.
    1. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: A 1- and 4-year prospective study. Schizophr Bull. 2005;31(1):167–74.
    1. Liberman RP, Glynn SM, Blair KE, Ross D, Marder SR. In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry. 2002;65(2):137–55.
    1. Maples NJ, Velligan DI. Cognitive adaptation training: Establishing environmental supports to bypass cognitive deficits and improve functional outcomes. Am J Psychiatr Rehabil. 2008;11(2):164–80.
    1. Milev P, Ho B, Arndt S, Andreasen N. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7 year follow-up. Am J Psychiatry. 2005;162(3):495–506.
    1. Mueser KT, Bellack AS, Morrison RL, Wixted JT. Social Competence in schizophrenia: Premorbid adjustment, social skill, and domains of functioning. J Psychiatr Res. 1990;24:51–63.
    1. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery: part 1. Test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–213.
    1. Riggs SE, Grant PM, Perivoliotis D, Beck AT. Assessment of cognitive insight: a qualitative review. Schizophr Bull. 2012;38(2):338–350.
    1. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166(23):141–147.
    1. Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull. 2014;40(S2):107–116.
    1. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof of concept study. JAMA Psychiatry. 2014;71(6):637–646.
    1. Velligan DI. Cognitive adaptation training: Targeted use of automatic and controlled processes to improve functional outcomes 2012. Schizophrenia Research. 136(S!):S375.
    1. Velligan DI, Diamond PM, Mueller J, Xueying L, Maples NJ, Wang M, Miller AL. The short term impact of generic versus individualized environmental supports on functional outcomes and target behaviors in schizophrenia. Psychiatry Res. 2009b;168(2):94–101.
    1. Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008a;102:312–19.
    1. Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YW, Castillo D, Miller AL, Maples NJ. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008b;34(3):483–93. .
    1. Velligan DI, Bow-Thomas CC, Huntzinger CD, Ritch J, Ledbetter N, Prihoda TJ, Miller AL. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry. 2000a;157(8):1317–23. .
    1. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis. 2000b;188(8):518–24.
    1. Velligan DI, Mahurin RK, Giesecke SL, Miller AL. The functional significance of symptomatology and cognitive dysfunction in schizophrenia. Schizophr Res. 1997;25:21–31.
    1. Velligan DI, Maples N, Roberts DL, Medellin EM. Integrated psychosocial treatment for negative symptoms. Am J Psychiatr Rehabil. 2014;17(1):1–19.
    1. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale: ‘The drift busters’. Int J Meth Psychiatr Res. 1993;3(4):221–244.
    1. Wise R. Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci. 1982;5(1):39–87.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する